Mediwound Ltd
NASDAQ:MDWD
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Estee Lauder Companies Inc
NYSE:EL
|
Consumer products
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Church & Dwight Co Inc
NYSE:CHD
|
Consumer products
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
American Express Co
NYSE:AXP
|
Financial Services
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Target Corp
NYSE:TGT
|
Retail
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
Mueller Industries Inc
NYSE:MLI
|
Machinery
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
7.67
21.16
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Estee Lauder Companies Inc
NYSE:EL
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Church & Dwight Co Inc
NYSE:CHD
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
American Express Co
NYSE:AXP
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Target Corp
NYSE:TGT
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
Mueller Industries Inc
NYSE:MLI
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one MDWD stock under the Base Case scenario is 10.75 USD. Compared to the current market price of 16.91 USD, Mediwound Ltd is Overvalued by 36%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Mediwound Ltd
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for MDWD cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Mediwound Ltd
Balance Sheet Decomposition
Mediwound Ltd
Current Assets | 37.3m |
Cash & Short-Term Investments | 29.2m |
Receivables | 4.9m |
Other Current Assets | 3.2m |
Non-Current Assets | 20m |
PP&E | 19.2m |
Intangibles | 132k |
Other Non-Current Assets | 691k |
Current Liabilities | 22.6m |
Accounts Payable | 2.7m |
Other Current Liabilities | 19.9m |
Non-Current Liabilities | 16.8m |
Long-Term Debt | 6.4m |
Other Non-Current Liabilities | 10.5m |
Earnings Waterfall
Mediwound Ltd
Revenue
|
20.1m
USD
|
Cost of Revenue
|
-17.5m
USD
|
Gross Profit
|
2.7m
USD
|
Operating Expenses
|
-17.8m
USD
|
Operating Income
|
-15.1m
USD
|
Other Expenses
|
-4.8m
USD
|
Net Income
|
-20m
USD
|
Free Cash Flow Analysis
Mediwound Ltd
USD | |
Free Cash Flow | USD |
In Q2 2024, MediWound achieved significant milestones, including the completion of a new manufacturing facility for NexoBrid, expected to be operational in 2025. Revenue for the quarter was $5.1 million, driven by Vericel's increased orders. However, net loss grew to $6.3 million, largely due to financial expenses from warrant revaluation. EscharEx received €16.25 million in European funding for its diabetic foot ulcer indication expansion, setting the stage for future trials. Additionally, the company secured $25 million in funding from Mölnlycke Healthcare, bolstering its financial position and strategic collaborations .
What is Earnings Call?
MDWD Profitability Score
Profitability Due Diligence
Mediwound Ltd's profitability score is 52/100. The higher the profitability score, the more profitable the company is.
Score
Mediwound Ltd's profitability score is 52/100. The higher the profitability score, the more profitable the company is.
MDWD Solvency Score
Solvency Due Diligence
Mediwound Ltd's solvency score is 54/100. The higher the solvency score, the more solvent the company is.
Score
Mediwound Ltd's solvency score is 54/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
MDWD Price Targets Summary
Mediwound Ltd
According to Wall Street analysts, the average 1-year price target for MDWD is 30.35 USD with a low forecast of 25.25 USD and a high forecast of 37.8 USD.
Dividends
Current shareholder yield for MDWD is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Profile
Country
Industry
Market Cap
Dividend Yield
Description
MediWound Ltd. is a biopharmaceutical company engaging in the development, manufacture, and commercialization of products to address needs in the fields of severe burns, chronic wounds, and other hard-to-heal wounds. The firm focuses on developing, manufacturing and commercializing therapeutics products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The firm's product, NexoBrid, is indicated for the removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns, also referred to as severe burns. The firm sells NexoBrid in Europe and Israel. NexoBrid is a topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues. Its product, EscharEx, is a topical biological drug, which is being developed for debridement of chronic and other hard-to-heal wounds. NexoBrid and EscharEx are based on its proteolytic enzyme technology. The firm is also developing an injectable product based on its proteolytic enzyme technology for connective tissue pathologies and indications.
Officers
The intrinsic value of one MDWD stock under the Base Case scenario is 10.75 USD.
Compared to the current market price of 16.91 USD, Mediwound Ltd is Overvalued by 36%.